{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-037214","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.881810+00:00","generated_at":"2026-06-22T02:12:30.707644+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"MAIA Biotechnology Q3 net loss narrows to $3.9M; cash of $14.1M supports 12-month runway","bullets":["Cash totaled $14.1M as of Sep 30, 2022, up from $10.6M at Dec 31, 2021; proceeds from July IPO added.","R&D expenses rose to $2.3M (Q3 2022) vs $1.1M (Q3 2021) due to THIO trial startup and clinical prep.","Net loss improved to $3.9M (Q3 2022) from $5.2M (Q3 2021), primarily due to prior-year loss on convertible notes.","Presented THIO-101 Phase 2 trial design at ESMO 2022; plans to report safety data in Q4 2022 and efficacy data in 2023.","Added to Longevity Stock Index; preclinical data for THIO in hepatocellular carcinoma presented at Triple Meeting Symposium."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-037214","json":"https://secwatch.observer/filing/0001564590-22-037214.json","markdown":"https://secwatch.observer/filing/0001564590-22-037214.md","text":"https://secwatch.observer/filing/0001564590-22-037214.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000156459022037214/0001564590-22-037214-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000156459022037214/maia-8k_20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T02:12:30.707644+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"43a8c95cdc701ccaa6d8db095e4a9d4cf8f08612","claim":"MAIA Biotechnology, Inc. reported third quarter ended September 30, 2022 results: net income Net loss was approximately $3.9 million.","evidence_excerpt":"MAIA Biotechnology Reports Third Quarter 2022 Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1878313/000156459022037214/0001564590-22-037214-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Net income","value":"Net loss was approximately $3.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}